No Data
No Data
Express News | The State Council has approved the "Implementation Plan for Supporting the Development of Innovative Drugs across the Whole Value Chain".
Midday Snapshot | The gains of the three major Hang Seng indexes narrowed, auto stocks were strong, and NIO Inc stock rose over 6%.
Golden industrial concept leads the gains, with Lingbao Gold up over 6%, Zijin Mining Group and SD Gold up over 4%, Zhaojin Mining and Chi Silver GP up over 3%.
Hualing Pharmaceuticals announced at the 2024 ADA Scientific Conference the potential of using Dapagliflozin in combination with SGLT-2 inhibitors.
Shanghai, June 24, 2024 / PRNewswire / - Hualead Pharmaceuticals ("Company", Stock Code: 2552.HK) announced today that the company and its wholly-owned subsidiary, Nanjing Shengderui Pharmaceutical Technology Co., Ltd. (Shengderui), showcased multiple basic research results at the 84th American Diabetes Association (ADA) Scientific Sessions. One basic research study showed that the global innovative drug, dual-acting glucokinase activator (GKA) Dugliglitine, can lower blood glucose levels by promoting insulin and GLP-1 secretion. Dugliglitine and SGLT-2 inhibitor Caglitinib were used in combination.
Midday glance| The three major indexes edged up slightly, with Bilibili leading the way in network technology, up nearly 5%; Chip stocks rose, Semiconductor Manufacturing International Corporation rose more than 3%.
Hong Kong stocks related to Apple suppliers continued to show strength, with Sunny Optical Technology rising more than 4%, AAC Technologies and BYD Electronic rising more than 3%; most China-affiliated brokerage stocks in Hong Kong rose, with Haitong Securities up nearly 4%.
HKEX Buzz: Hualei Pharmaceutical-B (02552) rose more than 4% and will exhibit multiple research achievements at the American Diabetes Association conference in 2024.
Hua Ling Pharmaceutical - B (02552) rose more than 4%, as of the time of publication, up 4.43% to HKD 1.65, with a turnover of HKD 1.684 million.
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
No Data